Swiss National Bank Increases Stock Holdings in ICU Medical, Inc. (NASDAQ:ICUI)

Swiss National Bank boosted its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 5.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 45,219 shares of the medical instruments supplier’s stock after buying an additional 2,400 shares during the quarter. Swiss National Bank owned approximately 0.19% of ICU Medical worth $8,240,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of ICUI. Innealta Capital LLC bought a new stake in shares of ICU Medical in the 2nd quarter worth $32,000. Hexagon Capital Partners LLC grew its position in ICU Medical by 162.7% in the 3rd quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 122 shares in the last quarter. Allworth Financial LP grew its position in ICU Medical by 100.0% in the 3rd quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 100 shares in the last quarter. EntryPoint Capital LLC increased its stake in ICU Medical by 731.5% in the 1st quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock valued at $48,000 after buying an additional 395 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its position in shares of ICU Medical by 46.4% during the 1st quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 173 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Raymond James upped their target price on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a report on Thursday, September 12th. KeyCorp raised their target price on ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, November 13th. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Jefferies Financial Group began coverage on shares of ICU Medical in a research note on Monday, October 14th. They issued a “hold” rating and a $183.00 target price on the stock. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, ICU Medical currently has an average rating of “Moderate Buy” and an average target price of $173.00.

Insider Transactions at ICU Medical

In other ICU Medical news, VP Daniel Woolson sold 2,502 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the transaction, the vice president now owns 13,107 shares in the company, valued at $2,139,324.54. This trade represents a 16.03 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Vivek Jain sold 12,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total value of $2,141,520.00. Following the sale, the chief executive officer now owns 104,593 shares in the company, valued at approximately $18,665,666.78. This represents a 10.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,502 shares of company stock worth $6,573,496 over the last quarter. Corporate insiders own 6.70% of the company’s stock.

ICU Medical Trading Down 0.4 %

Shares of ICUI opened at $167.81 on Tuesday. ICU Medical, Inc. has a fifty-two week low of $83.26 and a fifty-two week high of $196.26. The business has a 50-day moving average of $175.98 and a 200 day moving average of $146.15. The firm has a market cap of $4.11 billion, a P/E ratio of -36.72 and a beta of 0.66. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.